NervGEN Pharma ( NGENF ) is a public company. www.nervgen.com
NervGEN is unleashing the Nervous System to Repair and Heal Itself-Focusing on multiple sclerosis (MS), Alzheimer’s disease, spinal cord injury, stroke and traumatic brain injury (TBI). NervGEN’s technology is applicable to all Nervous System Diseases.
Based upon thirty years of research by Dr. Jerry Silvers Case University and Cleveland Clinic
PHD left AMGEN to become Chief Medical Officer of NervGEN Dr Dan Mikol. Reason: Dr Silvers 30 years of research
Founding and current Editor of Journal of Alzheimer’s Disease Dr George Perry is on the NervGEN Advisory Board
Dr George Perry has stated: “If you have a drug that actually changes the biology of the disease (i.e. NervGEN’s NVG -291) why do you need 100’s to see (in clinical trial)? …….NervGEN’s NVG-291 “may change the course of the disease…maybe not full recovery….. “I am actually quite enthusiastic.”
NervGEN likely to receive nondilutive financing from the Department of Defense for Traumatic Brain Injury (TBI) Research
Dr Michael Davis- (Retired Colonel) –Traumatic Brain Injury and the Department of Defense “The mechanism of this (NervGEN peptide NVG-291) is unique….it’s had significant preclinical validation in the central nervous system….… I feel very strongly that this has high likely chance of success”
‘Proven functional recovery demonstrated in 6 different disease models with benefits crossing multiple neurological functions’
NervGEN is developing a revolutionary new class of drugs that REPAIRS damage to the Nervous System and restores motor sensory and cognitive function. Currently there are no approved “neurorestorative” drugs.
Delivered systemically via injection, NervGen’s drug (NVG-291) REPAIRS the nervous system at the site of damage with a mechanism of action that results in multiple modes of repair-including regeneration, remyelination and enhanced plasticity.
NervGEN’s published results from animal models of damage and disease are unprecedented both in scope and magnitude of effect, including spinal cord injury, multiple sclerosis (MS), stroke, cardiac arrythmia and peripheral nerve injury.
Backed by three decades of scientific research by Dr. Jerry Silvers, NervGEN’s platform technology has the potential to redefine therapeutic outcomes for ALL central nervous system damage-including multiple sclerosis (MS), Alzheimer’s disease, spinal cord injury, stroke and traumatic brain injury (TBI).
NervGEN’s lead product, NVG-291, is the only drug of its kind in clinical development. Most nervous system drugs in development are aimed at stopping or SLOWING the progressive of the disease not REPAIRING. No treatment exists that “rewires” the damaged nerve connections and results in improvement.
NervGEN is hoping for Breakthrough Status from FDA on 3 fronts: Alzheimer’s Disease, MS and Spinal Cord Injury
In 2003 Dr Jerry Silvers was honored with the Christopher Reeve-Joan Irvine Research Medal (The Reeve-Irvine Medal) for critical contributions that may lead to the promotion of repair of the damaged spinal cord.
NervGen Pharma Zoom Presentation
See Mice Given NervGEN Drug NVG-291 – A MIRACLE
9:24 Spinal Cord Injury
41:02 Spinal Cord Injury
55.18 MS Multiple Sclerosis
Paradigm Capital NervGEN Analyst Report 10/13/21
Encode initiation report on NervGEN September 13, 2021
Revolutionary drug ‘could reverse damage’ caused by Alzheimer’s by allowing nerve cells to mend themselves, scientists say
Dr Jerry Silvers
NervGen’s Alzheimer’s Disease Clinical Advisory Board
George Perry, PhD ( Founding and Current Editor-in-Chief Journal of Alzheimer’s Disease)
Michael Weiner, MD (Published over 903 peer-reviewed articles)
NervGEN’s Multiple Sclerosis Clinical Advisory Board
Spinal Cord Injury Clinical Advisory Board
More Videos
**September 9, 2021 NervGen Annual Shareholders Meeting
CEO Paul Brennan 14:06 minutes Multiple preclinical predictors of human clinical success
Chief Medical Officer Dan Mikol Why he left Amgen to come to NervGen 18:30 to 33:10
CEO Paul Brennan Target indications are attractive markets with significant unmet needs 49:00
and upcoming Value Drivers 55:50
Dr. Michael R Davis 34:50 to 46:50 At 45:26 “I feel very strongly that this has high likely chance of success”
**June 18, 2021- NervGen’s Case for an Effective Alzheimer’s Treatment
New NervGEN Chief Medical Officer from AMGEN Dan Mikol MD PHD why he came to NervGEN
Dan Mikol–from Amgen
24:38 minutes to 37:40 minutes
Dr. George Perry NervGen (NGENF) Advisory Board and founding and current editor of the Journal of Alzheimer’s Disease:
“If you have a drug that actually changes the biology of the disease (i.e. NervGen’s NVG -291) why do you need 100’s to see (in clinical trial)? …….NervGen’s NVG-291 “may change the course of the disease…maybe not full recovery….. “I am actually quite enthusiastic.”
46:44 to 48:35 minutes
Rich McAry
59:11 minutes
Paul Brennan
1:43 one hour 43 minutes
**April 14 2021 NervGen WebCast includes introduction of Dr Michael Davis- (Retired Colonel) –Traumatic Brain Injury and the Department of Defense
“The mechamism of this (NervGEN peptide NVG-291) is unique….it’s had significant preclinical validation in the central nervous system…we really need to pursue preclinical work further.”
Dr. Michael R Davis 36:48 to 1:18:10
https://biopub-webcasts.s3.amazonaws.com/NervGen+April+14
**October 20, 2021- NervGen: A Key Update on New Phase 1 Data
NervGEN is hoping for Breakthrough Status from FDA on 3 fronts: Alzheimer’s Disease, MS and Spinal Cord Injury
‘Proven functional recovery demonstrated in 6 different disease models with benefits crossing multiple neurological functions’
Also there could be targets outside the Central Nervous System. Dr Jerry Silvers is on call. 30+ years of research
Chief Medical Officer Dan Mikol
“I actually feel the results of spinal cord injury are especially exciting because spinal cord injury is not a disease it is consequence of trauma and if you can show repair in this condition where there is damage to the nervous system why shouldn’t this approach work in the other central nervous diseases like MS and Alzheimer’s….”
**27 JAN 2021 – BioPub.co Presents: NervGen – Alzheimer’s in its Bombsights
**16 DEC 2020 – NervGen WebCast: Maximizing Value, NervGen’s Indication Strategy and Operational Update
**26 JUN 2020 – BioPub.co Presents: Dr. Jerry Silver -BioPub’s “Evergreen” Scientist of the Year
adamr826 